542 related articles for article (PubMed ID: 24054424)
1. Cutaneous melanoma.
Eggermont AM; Spatz A; Robert C
Lancet; 2014 Mar; 383(9919):816-27. PubMed ID: 24054424
[TBL] [Abstract][Full Text] [Related]
2. [What's new in skin cancers?].
Jouary T
Ann Dermatol Venereol; 2014 Dec; 141 Suppl 4():S630-42. PubMed ID: 25539755
[TBL] [Abstract][Full Text] [Related]
3. BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy.
Barbour AP; Tang YH; Armour N; Dutton-Regester K; Krause L; Loffler KA; Lambie D; Burmeister B; Thomas J; Smithers BM; Hayward NK
Eur J Cancer; 2014 Oct; 50(15):2668-76. PubMed ID: 25070294
[TBL] [Abstract][Full Text] [Related]
4. BRAF mutation-positive folliculotropic metastatic melanoma.
Brick KE; Halling KC; Khan YK; Peters MS
Am J Dermatopathol; 2013 Jul; 35(5):609-12. PubMed ID: 23715079
[TBL] [Abstract][Full Text] [Related]
5. Upcoming strategies for the treatment of metastatic melanoma.
Spagnolo F; Queirolo P
Arch Dermatol Res; 2012 Apr; 304(3):177-84. PubMed ID: 22350184
[TBL] [Abstract][Full Text] [Related]
6. [What's new in dermato-oncology?].
Basset-Séguin N
Ann Dermatol Venereol; 2011 Dec; 138 Suppl 4():S253-62. PubMed ID: 22202647
[TBL] [Abstract][Full Text] [Related]
7. Frontline approach to metastatic BRAF-mutant melanoma diagnosis, molecular evaluation, and treatment choice.
Chapman PB; Hauschild A; Sondak VK
Am Soc Clin Oncol Educ Book; 2014; ():e412-21. PubMed ID: 24857132
[TBL] [Abstract][Full Text] [Related]
8. Melanoma - a management guide for GPs.
Thompson JF; Scolyer RA; Kefford RF
Aust Fam Physician; 2012 Jul; 41(7):470-3. PubMed ID: 22762064
[TBL] [Abstract][Full Text] [Related]
9. [Immunotherapies and melanoma].
Routier É; Robert C; Mateus C
Bull Cancer; 2014 Dec; 101 Suppl 2():S13-24. PubMed ID: 25776763
[TBL] [Abstract][Full Text] [Related]
10. Is BRAF a prognostic factor in stage III skin melanoma? A retrospective study of 72 patients after positive sentinel lymph node dissection.
Picard M; Pham Dang N; D'Incan M; Mansard S; Dechelotte P; Pereira B; Mondie JM; Barthelemy I
Br J Dermatol; 2014 Jul; 171(1):108-14. PubMed ID: 24602025
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond.
Menzies AM; Long GV
Eur J Cancer; 2013 Oct; 49(15):3229-41. PubMed ID: 23870385
[TBL] [Abstract][Full Text] [Related]
12. Current and planned multicenter trials for patients with primary or metastatic melanoma.
Sondak VK; Han D; Deneve J; Kudchadkar R
J Surg Oncol; 2011 Sep; 104(4):430-7. PubMed ID: 21858839
[TBL] [Abstract][Full Text] [Related]
13. New drugs in melanoma: it's a whole new world.
Eggermont AM; Robert C
Eur J Cancer; 2011 Sep; 47(14):2150-7. PubMed ID: 21802280
[TBL] [Abstract][Full Text] [Related]
14. Systemic treatment of metastatic melanoma: new approaches.
Hamid O; Boasberg PD; Rosenthal K; O'Day SJ
J Surg Oncol; 2011 Sep; 104(4):425-9. PubMed ID: 21858838
[TBL] [Abstract][Full Text] [Related]
15. The Sunbelt Melanoma Trial.
McMasters KM
Ann Surg Oncol; 2001 Oct; 8(9 Suppl):41S-43S. PubMed ID: 11599897
[TBL] [Abstract][Full Text] [Related]
16. (Neo)adjuvant systemic therapy for melanoma.
van Zeijl MC; van den Eertwegh AJ; Haanen JB; Wouters MW
Eur J Surg Oncol; 2017 Mar; 43(3):534-543. PubMed ID: 27453302
[TBL] [Abstract][Full Text] [Related]
17. Advances in the management of melanoma: targeted therapy, immunotherapy and future directions.
Dean E; Lorigan P
Expert Rev Anticancer Ther; 2012 Nov; 12(11):1437-48. PubMed ID: 23249108
[TBL] [Abstract][Full Text] [Related]
18. [Detection of residual microscopic disease in melanoma: interest of the sentinel lymph node procedure?].
Mateus C; Thomas M; Robert C
Bull Cancer; 2014 Apr; 101(4):354-7. PubMed ID: 24793626
[TBL] [Abstract][Full Text] [Related]
19. Melanoma and immunotherapy.
Eggermont AM; Schadendorf D
Hematol Oncol Clin North Am; 2009 Jun; 23(3):547-64, ix-x. PubMed ID: 19464602
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Advances and Treatment Options in Metastatic Melanoma.
Johnson DB; Sosman JA
JAMA Oncol; 2015 Jun; 1(3):380-6. PubMed ID: 26181188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
